Curated News
By: NewsRamp Editorial Staff
April 24, 2025
Soligenix's HyBryte™ Shows 75% Response Rate in Skin Cancer Trial
TLDR
- HyBryte™ by Soligenix shows 75% response rate in treating CTCL, potentially capturing a significant market share.
- HyBryte™ uses visible light to treat CTCL, showing promising results in 18 weeks with a safer profile.
- Soligenix's HyBryte™ offers hope to CTCL patients with faster, safer, and more effective treatment options.
- Soligenix's HyBryte™ shows impressive results in treating a rare form of skin cancer, marking a breakthrough in medical innovation.
Impact - Why it Matters
This news matters as Soligenix's innovative skin cancer treatment has the potential to offer a faster, safer, and more effective solution for CTCL patients, addressing a critical unmet need in the market. With promising clinical data and government funding support, HyBryte™ could significantly impact the lives of those suffering from this chronic, incurable disease.
Summary
Soligenix (NASDAQ: SNGX) announces positive results for its skin cancer treatment, HyBryte™, with 75% of patients seeing significant improvement in treating CTCL after just 18 weeks. The treatment shows promise in real-world testing, with six out of eight patients showing major improvement in skin lesions and three achieving a complete response.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Soligenix's HyBryte™ Shows 75% Response Rate in Skin Cancer Trial
